Core Viewpoint - China National Pharmaceutical Group announced the acquisition of Hejia, expanding its presence in the siRNA sector, with a maximum base price of RMB 1.2 billion [1][3][10]. Company Overview - Hejia is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs, with a comprehensive drug development system from target discovery to clinical proof of concept [3][10]. - The company targets chronic diseases in three main areas: weight loss metabolism, cardiovascular, and neurological systems [3][10]. Market Potential - The global transaction volume in the siRNA field is expected to exceed USD 35 billion by 2025, with a year-on-year growth rate of over 40% [11]. - The acquisition aims to build a next-generation cardiovascular treatment product line and enhance the metabolic field, expanding into the trillion-dollar chronic disease management market [11]. Technological Advancements - Hejia has developed a differentiated delivery platform covering multiple tissues, with proprietary intellectual property [4][11]. - The core platform, MVIP (Multivalent Import Platform), is the first clinically validated liver-targeted delivery platform capable of achieving "one injection per year" for chronic disease treatment, addressing adherence issues [11][12]. - DDP (Dual Delivery System) technology overcomes the industry challenge of dual-target efficacy, applicable to various tissues, and aims to address complex or refractory diseases [12]. - The NSDP (Neuro System Delivery Platform) targets the central nervous system and aims for a "one injection per year" delivery frequency [12].